Minneapolis, MN – According to filings with the U.S. Securities and Exchange Commission, Emerging Therapy Solutions is raising $2,982,403.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Mclean played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Emerging Therapy Solutions

ETS provides a fully outsourced solution for the payer community related to gene and cell therapies.  ETS provides clinical trial pipeline curation, exposure analytics, medical policy and care guidelines developed and recommended by expert physicians, patient placement and tracking, credentialed centers, educational forums, as well as contract and claim solutions.

To learn more about Emerging Therapy Solutions, visit http://emergingtherapies.com/

Contact:
David Mclean, Chief Executive Officer
612-371-3507

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved